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Abstract
Imaging biomarkers capable of early quantification of tumor response to therapy would provide an opportunity
to individualize patient care. Image registration of longitudinal scans provides a method of detecting treatment-
associated changes within heterogeneous tumors by monitoring alterations in the quantitative value of individual
voxels over time, which is unattainable by traditional volumetric-based histogram methods. The concepts involved
in the use of image registration for tracking and quantifying breast cancer treatment response using parametric
response mapping (PRM), a voxel-based analysis of diffusion-weighted magnetic resonance imaging (DW-MRI)
scans, are presented. Application of PRM to breast tumor response detection is described, wherein robust regis-
tration solutions for tracking small changes in water diffusivity in breast tumors during therapy are required.
Methodologies that employ simulations are presented for measuring expected statistical accuracy of PRM for
response assessment. Test-retest clinical scans are used to yield estimates of system noise to indicate significant
changes in voxel-based changes in water diffusivity. Overall, registration-based PRM image analysis provides
significant opportunities for voxel-based image analysis to provide the required accuracy for early assessment
of response to treatment in breast cancer patients receiving neoadjuvant chemotherapy.
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Introduction
Advances in functional imaging along with molecularly targeted
probes and contrast agents are providing feature-rich data sets from
multiple sources before and following treatment that allow for greater
detail in the characterization and interrogation of the cancer disease
process [1]. However, in spite of the increased toolbox of techniques
for evaluating a patient’s tumor response, the clinical standard assess-
ment tool for measuring tumor treatment response is the Response
Evaluation Criteria in Solid Tumors (RECIST) [2]. The RECIST clini-
cal response metric is extensively used on anatomic tumor images
acquired by computed tomography (CT) and magnetic resonance im-
aging (MRI) scans wherein linear measurements of the longest diameter
of a tumor (or sum from multiple tumors) are obtained to compute
an objective endpoint. Improvements in patient-specific imaging-based
response metrics that allow for earlier detection of overall cancer re-
sponse will require sensitive readouts that can be quantified and ulti-
mately correlated with RECIST clinical trial outcome measures [3].
While the use of imaging to anatomically characterize tumor dimen-
sions has been fundamental to the integration of imaging within clinical
trial design and routine clinical practice, alternative MR image–derived
functional tumor response metrics that may provide for more sensitive
and thus earlier response readouts have emerged. These metrics in-
clude, for example, hemodynamic [dynamic susceptibility contrast
(DSC)-MRI and dynamic contrast enhanced (DCE)-MRI] and water
diffusion-weighted magnetic resonance imaging (DW-MRI) readouts
of overall tumor response [4–6]. Response assessment using these scan
modalities is commonly done through obtaining image-derived sum-
mary metrics that are extracted from whole tumor volume-of-interest
(VOI) contours and histogram analysis of the quantitative voxel values
contained within the target lesion (Figure 1) [7]. Histogram analysis
allows for quantification of the image VOI using, for example, the
mean value where tumor response is quantified by the magnitude of
change from baseline following treatment. While whole-tumor met-
rics can be robust measures when tumor changes are relatively homo-
geneous, these VOI-based measures may be less sensitive for detecting
treatment-associated changes in longitudinally acquired scans in the
presence of intratumor heterogeneity where local changes are spatially
varying within the mass. As shown in Figure 1, changes in tumor his-
togram MR metrics can be minimal (Figure 1A) and uniformly shifted
(Figure 1B) with a corresponding net shift in the mean histogram
values or have similar numbers of voxels with increased and decreased
values, thus nullifying the overall histogram shift (Figure 1C). How-
ever, spatial alignment of interval images using image registration algo-
rithms provides an opportunity to use the spatial information contained
within the images to track quantitative changes in individual voxels.
Individual voxels with paired, temporally resolved, quantitative values
generate a joint density histogram where the axes are quantitative values
for the baseline scan (x-axis) versus the follow-up scan ( y-axis). Applica-
tion of a statistically derived cutoff of significant change [95% con-
fidence interval (CI)] provides for classification of voxels allowing for
a voxel-based method capable of tracking changes in the underlying
imaging metric over time (Figure 1, D–F). Figure 1 shows simulated
histograms of water diffusivity, quantified as the apparent diffusion
coefficient (ADC), within the tumor VOI along with corresponding
Figure 1. A simulated comparison of whole-tumor histogram analysis (top row; the blue line is the pretreatment tumor data and the
red line is the posttreatment tumor data) versus the corresponding voxel-based analysis using a joint density histogram (bottom row).
Histograms from tumors with (A) no major change, (B) significant uniform shift to higher ADC values with a 34% net mean change, and
(C) increased and decreased ADC values resulting in no net detectable histogram shift. Parametric response maps from the corresponding
histograms above where (D) the CI for detection of change was set to 95%, thus no significant change in red voxels (increased values) or
blue voxels (decreased values) was detected. (E) An increase in the number of red voxels was detected at 29% of the total tumor voxels.
(F) Both an increase and a decrease in tumor voxels of approximately 15% were detected, whereas no major shift was detected using a
histogram analysis of the same data (C).
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simulated joint density plots for the tumors in which pretreatment
images have been registered with their corresponding posttreatment
images such that eachmeasured ADCvoxel at baseline has a paired value
at follow-up. The capability of applying a voxel-based analysis to “un-
mix” the complex biologic responses of individual tumors to treatment
will improve statistical accuracy in detecting tumor changes and further-
more will provide the ability to spatially assess treatment response re-
gionally within the lesion.
The initial application of voxel-by-voxel analysis was reported as the
functional diffusion map (fDM) that was developed as a statistical ap-
proach for segmenting brain tumor response based on a defined thresh-
old of ADC change following therapy [8].More recently, the voxel-based
method for processing longitudinally acquired MRI scans was further
generalized to multimodal applications including DSC-MRI wherein
it was shown to provide enhanced sensitivity for early cancer treatment
response over VOI-based metrics [9]. While early application of the
voxel-based methods was termed fDM as it was applied to DW-MRI
scans [8,10–12], more recently it has been referred to as parametric
response mapping (PRM) as it can be generalized and applied to
multiple imaging modalities [MRI, positron emission tomography
(PET), CT, etc.] [9,13–15].
DW-MRI can be applied to patients with breast cancer in an effort
to derive an early treatment response biomarker. For voxel-based
PRM analysis of ADC maps (PRMADC) to be applied, registration
of breast MR images and ADC maps must be accomplished. The
motivation for this research effort lies in the fact that patients who
elect to undergo neoadjuvant chemotherapy (NAC) do so with the
intent purpose of down-staging their disease before surgical resection
[16–18]. However, patients and physicians can be hesitant to use
NAC as it is not 100% effective, and since treatment response is
determined late or on completion of therapy, patients may not receive
timely effective intervention [19–21]. Therefore, immediate surgical
resection remains the standard approach, even in patients who are
known to be candidates for chemotherapy postoperatively. Having
an early imaging treatment response biomarker available would make
NAC more compelling and would improve the overall management of
this patient population. In an effort to advance this concept, analytical
algorithms for routine execution of PRMADC (e.g., image registration)
must ultimately be developed and tested in a multicenter setting to
validate PRMADC as an early quantitative imaging biomarker for breast
cancer patients undergoing NAC.
The overarching goal of the current report is to advance the PRM
imaging biomarker through consideration of interrelated issues and
procedures required to develop, validate, and implement voxel-based
imaging software applications for integrating the PRM biomarker
within the clinical environment. Considerations will address the types
of digital image registration available, the overall concepts of how
image registration works, the accuracy of image registration, the pro-
cedures for proper alignment of images, and finally determination of
thresholds for detection of significant change along with visualization
of results and quantification of summary response metrics.
Methods
Image Registration for Response Detection
Voxel-based analysis is predicated on the ability to align tumor
volumes acquired between interval exams such that homologous voxels
of the different temporal instances contain approximately the same
partial volumes of tissue. In the past 25 years, image registration in
biomedical applications has become increasingly used [22–25]. While
perhaps the most common use of registration has been in the field of
radiation treatment planning [26], registration methods have been
slower to move into general clinical practice. In our National Institutes
of Health (NIH)-sponsored quantitative imaging network (QIN)
research effort, we are developing the use of deformable registration
solutions for providing early imaging biomarker readouts of breast
cancer treatment response [27].
Selecting and Implementing Registration Algorithms
Due to the inherent complexity of the problems encountered in
the field of image registration, registration methods are selected to
suit the body part and the types of images to be registered, requiring
a cost (or objective) function, deformation function, optimization
scheme, and in many cases a smoothness penalty to control for too
many degrees of freedom in the chosen deformation function such as
cubic B-splines. A wealth of registration options, cost metrics, and
deformation functions are available (Table 1) and are summarized
in the literature [24,28]. Transforms can be grouped into those de-
rived from physical models, interpolation theory, or knowledge-
based. Cost/objective metrics can be described as iconic, based on
voxel values, or geometric using other image features. For each trans-
formation solution, there is the option of applying additional task-
specific constraints to insure that the physical domain is modeled
and the registration solution can accommodate anticipated situations,
such as smoothness of the deformation, tumor growth, tumor in-
filtration, or possibly slip boundaries. The specific selection from
Table 1. Components of the Registration Process.
Warping Deformation Transforms for Registration
Physical transform models Elastic body transformations
Viscous flow models





Radial basis functions: TPSs, Gaussian, Wendland, Wu
Elastic body splines
Free-form deformations include cubic B-splines
Basis functions from signal representation include Fourier
basis function, wavelets, Riesz
Locally affine
Knowledge-based Statistically constrained geometric transforms include
deformation atlases
Geometric transforms inspired by biomechanical/
biophysical models
Criteria Driving Registration (Metric or Cost Function)
Iconic metrics Difference type metrics (fast, assumes identical relationship
between voxels or measures), sum of squared difference,
attribute vectors
Information theoretic models (single or multimodality)
include mutual information, entropy
Correlation coefficient type metrics (linear or reduction to
linear relationship between corresponding voxels)
Geometric methods Detecting points/regions of interest and mapping:
Laplacian of Gaussian, Lowe’s scale invariant feature,
exact/inexact landmark mapping
Feature mapping using other methods: transform invariant
features matched using thresholds or graph matching
Hybrid methods Geometric information as initialization
Geometric information as constraint
Coupled approaches (unified iconic and geometric constraints)
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the possible combinations of choices is determined by the specific task,
accuracy, and computational speed required to reach the final solution.
The process is graphically shown in Figure 2. Here, two separate
images (Figure 2A) are identified where one (homologous image) is
spatially aligned to another (reference image). The extent of defor-
mation required to spatially align the two images is presented by
the grid (Figure 2A, top row). To solve the registration problem,
determination of the warping transform W that maps each point
in the reference to its homologue in the target space is accomplished.
After finding the transform, the homologous image is reconstructed
into the reference space using an inverse warping reconstruction,
W (p), yielding two matched images (Figure 2A, bottom row). When
a voxel maps into a space between several voxels, an interpolation
method is applied to find the proper value. Interpolation methods
range from picking the nearest neighbor to using an interpolation
method between the closest voxels, usually selected to match the type
of data being mapped, and the appropriate selection of values to avoid
creation of spurious values or altering a property of the data set, such as
mass. Registrations optimize W based on a cost function, C (Fig-
ure 2A), to yield two data sets of the same dimensions, i.e., the same
coordinate space, so that voxels in the same location represent the
same element in space. Overall, the warping deformation transform
(W ) must accommodate anticipated deformations such as tumor
growth with associated tissue displacement (Figure 2B, top), changes
involving infiltration into surrounding tissue (Figure 2B, middle), and
finally while not common in tumors, a deformation involving a slip
boundary (Figure 2B, bottom).
Many different approaches can be implemented to solve breast
registrations, with the caveat that assumptions should be chosen care-
fully and algorithm parameters tuned to the solution of the problem
being solved. Rueckert’s early deformable multimodal breast registra-
tion method used an affine transform followed by geometric free-
form deformations interpolated with B-splines and optimized using
normalized mutual information along with a smoothness penalty to
register contrast-enhanced MRI of the breast [29]. Biomechanical
models of the breast used finite-element modeling to corroborate
Rueckert’s method [30]. The algorithm was modified to add an in-
compressibility penalty to handle contrast changes in soft tissues
[31]. More recent approaches use modality-independent feature mea-
sures such as Gabor features [32]. Optical flow with brightness shift
term to account for contrast concentration has also been used and
corroborated using synthetic phantoms with expected biomechanical
properties [33,34]. An additional tumor-focused registration approach
using a radial basis function transform with a tunable global elasticity
parameter and tumor-specific stiffness constraint driven by mutual in-
formation has also been reported [35] along with a Laplacian physical
model of diffusion using a finite element framework [36]. Emerg-
ing registration solutions are focused on joint segmentation and
registration [37], incorporating information priors, expanded use of
modality-independent metrics, and speed through parallelism or other
computational efficiencies [38].
Registration Approach Developed for Breast Cancer
PRM Analysis
In this paper, we have developed and implemented breast tumor
registration thin-plate splines (TPSs), a geometric transform from
interpolation theory that, while computationally costly, has the benefit
of incorporating least-bending energy smoothness into its formulation
without penalizing the cost/objective function. Furthermore, we incor-
porated mutual information as the cost function to register anatomic
images to DW-MRI–derived ADC maps. Because of variable defor-
mity of tumor and breast tissue, registration was achieved locally around
the tumor by dilating the tumor’s VOI by a few voxels (three to five)
to allow the algorithm to “see” and match the border of the tumor.
A Nelder-Mead simplex algorithm was used to optimize the solution.
Although found to be computationally more expensive than alter-
natives, this algorithm has been shown to generate robust solutions
[39]. Preservation of topology was assured by removal of transform
control points that generate folding as measured by the presence of
a negative Jacobian, i.e., folding. This approach supports the use of
TPS with spatially varying degrees of freedom (DOF; using control
point density) initialized to that supported by the maximum local
Figure 2. (A) A warp transform defines the relationship between a
homologous and a reference image, where reference is the baseline
image and the homologous is a later time point or different modality.
To create an unwarped version of the homologous image, the loca-
tion of the pixel p is found in the homologous image as W (p) and
its value (orange) is inversely mapped back to create a registered
homologous image. (B) The warp transform W should be able
accommodate expected deformations including growth with dis-
placement of tissue (top) and infiltration into surrounding tissue
(middle). Another deformation not typically found in breast tissue
is a slip boundary (bottom).
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mutual information (MI) density but able to adapt to lower local MI
that only supports lower DOFs through the automatic local removal
of control points in such regions. A cubic B-spline approach would
mirror this approach by spatially adapting the smoothness penalty
term. Overall, this registration method provides the benefit of a maxi-
mally smooth radial basis function transform of varying local DOF
optimized by a voxel-based metric.
Clinical Trial Data
These studies had institutional review board approval, and in-
formed consent was obtained from all patients. The University of
Michigan QIN research effort relies on the use of image data ob-
tained from several multicenter prospective clinical trials including
a Cancer Research UK–sponsored trial (Neo COMICE) entitled
“Establishing the Efficacy of Advanced Semi-automated Functional
MR Imaging in the Early Prediction of Response of Locally
Advanced Breast Cancer to NAC”, the USA-based I-Spy 2 trial enti-
tled “An adaptive breast cancer trial design in the setting of NAC”, and
SWOG-S0800 substudy trial focused on diffusion-weighted imaging
(DWI) as well as data collected at the University of Michigan. The
SWOG-S0800 trial enrolled women with Her-2 negative inflammatory
breast carcinoma or Her-2 negative locally advanced breast carcinoma.
In addition, patients who were accrued as part of the SWOG-S0800
underwent test-retest examinations to provide image data required
for evaluating the overall accuracy or variability of the PRM approach.
Data presented in this current research effort were derived from the
Neo COMICE and SWOG-S0800 trials.
Figure 3. Image registration capture range and accuracy can be determined using MR breast images. A breast DW-MRI image
(low-gradient “b value” image) is (A) deformed using a 3 × 3 × 3 uniform grid to form a synthetic test data set (B) where the deforma-
tion is visualized by the grid in (C) with a mean absolute deformation of 17.6 mm. The deformation was repeated with 70 different
synthetic data sets with a range of mean absolute deformations. Applying our registration algorithm to these pairs with a known solution
resulted in (D) that plots the original deformation and registered mean deformation (0 is perfect registration). The 95% CI in (E) is plotted
in linear coordinates in (F) showing good repeatability with accuracy of <0.2 mm at 4 mm of original mean deformation and <0.5 mm for
values of original mean deformation of up to 16 mm. Note that mean deformations of 4 mm indicate deformation significantly higher
than that value in some regions.
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For the SWOG-S0800 trial, MR data was acquired on Achieva
and Ingenia 3T Philips MRI systems using 7-channel and 16-channel
dedicated breast coils. Nominal sequence parameters were as follows:
three-axis, diffusion-weighted, single-shot single spin-echo, echo-planar
imaging; TR = 4000 to 5000 ms; TE minimum = 55 to 80 ms;
SENSE = 2 or 3; b values = 0, 100, 600 s/mm2; bilateral axial scans
with FOV of 35 to 40 cm adjusted to patient size; SPAIR fat suppres-
sion; slice thickness = 4 mm; acquisition matrix of 160 to 184; number
of averages adjusted for a 4- to 5-minute scan. The diffusion maps were
not corrected for gradient nonlinearity.
Results
Assessment of Registration Accuracy
An important step in validating a response assessment tool based
on registration is to analyze and optimize the registration algorithm
used. This step can be difficult as the same cost functions used to
register images should not be used to assess the registration. A better
measure of registration quality would be independent of the registra-
tion solution and relevant to the image pair under consideration.
For example, difference maps might illustrate registration accuracy
if the images are from the same modality but would not be ap-
propriate to evaluate an anatomic MR image with a co-registered
contrast-enhanced scan due to expected signal changes from the
presence of contrast media that might be interpreted as misregistra-
tion. Evaluation of accuracy remains an ongoing research topic;
however, simulations can yield valuable insights into the overall
registration performance.
Accuracy, repeatability, capture range, and risk of nonconvergence
can be measured using synthetic data (phantom, computer-simulated)
to determine how accurately and consistently the method recovers a
known solution. Such tests generate accuracy results measured at the
voxel or subvoxel level, often as a mean and SD from a set of known
matching locations. To measure our breast registration effectiveness,
we generated a set of 70 synthetic phantoms of known, artificially
deformed breast images using a 3 × 3 × 2 grid of features randomly
perturbed to drive a TPS warp of the data set with no folding using SD
values between 3 and 15 mm resulting in a spectrum of mean absolute
deformations between 2 and 24 mm. Figure 3A shows the original
data set (from an isotropic diffusion MR acquisition), Figure 3B
shows one simulated phantom, and Figure 3C shows the resulting
deformation grid. Our registration algorithm was then used to com-
pute an optimized registration to “unwarp” each synthetic phantom to
match the original image using a 4 × 4 × 2 grid, i.e., an intentionally
different number and loci of control points than those used to create
the synthetic phantoms. Because the original 3 × 3 × 2 grid locations
are known for each phantom data set, we could back-compute the
locations in each “unwarped” phantom to compare locations and
measure the accuracy in mean and SD (measured in mm). The
mean absolute deformation was then computed over the original
and “unwarped” 3 × 3 × 2 locations across the 70 data sets. Registra-
tion capture to subvoxel accuracy was accomplished consistently for
phantoms with mean absolute deformations less than 17 mm (Fig-
ure 3D). The detail view of Figure 3D using a log scale in Figure 3E
illustrates the homoscedastic 95% CI for registration. The 95% con-
fidence limits (definition of repeatability) were determined to be [+0.1,
−0.7] or less than 0.2 mm at 4 mm original mean deformation and
[+0.31, −0.2] or less than 0.5 mm for values of original mean defor-
mations up to 16 mm. End of the robust automatic capture range is
noted at the threshold of 17 mm mean absolute deformation obtained
using a local maximum deformation of 46.51 mm at one of the 3 ×
3 × 2 initial control points.
Voxel-Based PRM
To accomplish PRM analysis of DW-MRI breast ADC maps,
multiple data sets must be co-registered across one or more time points
to apply voxel-based methods for determining change in diffusion
values as a response metric. PRM is based on co-registration of voxel
pairs (or vectors if more than one modality is used) that can be visu-
alized using a joint density histogram for a region of interest, in our
application a tumor VOI. This distribution contains joint informa-
tion about the changes. Measures of detectable change can thus be
computed as well as displayed as a color overlay of the spatially
varying changes over the anatomic image.
To identify response in breast tumor ADC maps that are measured
at several points in a treatment cycle, co-registration of ADC maps
Figure 4. Registration of ADC maps over time requires a two-step process where ADC images are initially mapped to post-contrast
anatomic scans within each time point to handle motion and susceptibility artifacts. Anatomic images are then registered, and the
resulting transform was applied to ADC data. Registrations are computed locally in the tumor and surrounding region.
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must be accomplished for subsequent PRM analysis (Figure 4). The
approach undertakes an initial registration of the ADC map with the
corresponding anatomic image to correct for any misalignment during
MRI reconstruction due to susceptibility artifacts and patient motion.
Successive ADC maps are registered to the baseline ADC. The result is
a set of registered ADC images from which PRM metrics can be com-
puted for analysis of treatment-induced change. When changes are
minimal, as is the case here when imaging over short intervals, multi-
ple images can be co-registered into the same space. However, when
larger changes in tumor dimensions are expected, images may need
to be registered pairwise.
Detection of ADC changes in the tumor requires a threshold that
defines a significant change in ADC beyond system noise and mis-
registration. Our approach used a test-retest procedure where a patient
was scanned twice within a short interval of time (t < 30 min), having
been removed from the scanner between scans. Shown in Figure 5A
is a representative example of a test-retest exam of a patient with
breast cancer obtained from the SWOG-S0800 clinical trial where
T2w images from the patient that were acquired before treatment
initiation are shown. The tumor is evident within the VOI. Following
registration of the two ADC maps, PRM analysis is accomplished
using a joint density plot (Figure 5B) that provides a representation
of the overall variability of the measurement. A perfect solution
obtained in the absence of noise would yield a result wherein all voxel
pairs would have the same value and would converge on the diagonal
line of equality (dashed line in Figure 5B) in the joint density plot of
Figure 5. Joint density histogram error analysis of registered tumor ADC values using test-retest MR scans. (A) A set of test-retest T2w
images of a breast cancer patient with the tumor delineated by a VOI overlay. (B) The joint density plot of the two exams reveals the
distribution of differences between the exams about the dashed line of unity. (C) A cohort of 10 SWOG-S0800 patients who underwent
test-retest examination followed by image registration and determination of the 95% CI is each shown as an individual point on the plot.
An average CI of 0.45 × 10−3 mm2/s was found and (D) applied to a joint density histogram analysis (PRM) of tumor ADC maps from the
same patient shown in (A) using the pretreatment data as the baseline (abscissa) plotted against the posttreatment ADC values of the
tumor (ordinate). The values for each PRM classification are shown.
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the two scans. In the real world, principle component analysis can be
used on the distribution to identify the major axis of correspondence
for the test-retest, and a CI for change can be computed using a percent
measure (generally 95%). Determination of the 95% CI can be accom-
plished and values across the test-retest group of patients can be used to
generate an average CI for future patients who do not have test-retest
data available (Figure 5C). We determined that the average 95% CI for
breast cancer patient test-retest data sets using the SWOG-S0800 data
(n = 10 patients) was ±0.45 ADC units. When comparing a follow-up
scan with a baseline scan from the same patient, the average CI limit
can be applied to classify individual voxels based on increasing (red
voxels, PRMADC+), decreasing (blue voxels, PRMADC−), and un-
changed (green voxels, PRMADC0) ADC values (Figure 5D). PRM
measures are therefore presented as relative percent volumes by sum-
ming all voxels within a class and normalizing by the total VOI volume
(number of voxels). In Figure 5D, the color PRM overlay on the T2w
image reveals the spatial distribution of PRM classifications within
the individual tumor slice. In this test-retest example using the average
cutoff for significant change derived from the average of 10 patients
(±0.45 ADC units), values of PRMADC+, PRMADC−, and PRMADC0
were 6%, 2%, and 92%, respectively.
The test-retest scheme may not be feasible within a typical clinical
scanning environment (e.g., patients may not be willing to undergo
the additional examination effort, time is not available for repeat
scans, etc.), and using an average threshold for significant change
that is derived from a pool of test-retest data may provide the most
expeditious approach for determination of an overall CI for a modal-
ity. A pool of test-retest results can therefore be used to determine a
globally applicable CI. Shown in Figure 6 is an example where the
CI was determined using a training set of test-retest images derived
from SWOG-S0800 patients and applied to Neo COMICE–derived
registered patient scans. In this example, it is clearly evident that a
region of large increase in ADC values could be identified within
the tumor mass indicating a positive treatment response in that
region (PRMADC+ = 11%). As shown in Figure 6, the voxel-based
PRM methods provide a value for increased ADC within the tumor
(PRMADC+) that can be used as a metric for assessing treatment
response but also provide for spatially identifying the regions of change
within the three-dimensional tumor mass.
Discussion
We have applied fDM and PRM in multiple research domains,
developing the method in animal tumor models [40–42] and translat-
ing it into human applications including brain cancer, head and neck
cancer, metastatic cancer to the bone, and primary breast tumors [8–
10,15,39,43,44]. The challenge in each case is to validate all com-
ponents of the method: imaging, registration, and response mapping
for change detection. The test of this or any other alternative measure
of tumor response is its applicability across modalities and imaging
centers in a repeatable and robust manner. Consistent imaging pro-
tocols that provide repeatable, quantitative readouts are important for
applying PRM across clinical settings. As part of the QIN effort, we
have developed MRI phantoms and gradient nonlinearity corrections
aimed at improving the quantification of DW-MRI [45,46] to opti-
mize quantitative PRMADC metrics for accuracy in detection of treat-
ment-associated changes. Such quality control measures along with
careful consideration of possible artifacts associated with acquisition
protocols and post-processing algorithms will provide a solid foun-
dation for advancing voxel-based imaging procedures at multiple
institutions [7]. Calibration must occur regularly and imaging proto-
cols should be rigorously adhered to for optimization of the PRM
imaging biomarker.
PRM tumor response analysis requires robust image registration in
order for quantification of change to be made on a voxel-by-voxel
Figure 6. The overall process of quantitative PRM analysis of tumor treatment response. Two sets of image acquisitions are undertaken
on an individual patient, pretreatment (baseline) and at some time interval posttreatment initiation. A VOI is drawn defining the tumor
boundaries on the images that are subsequently dilated by the software to include sufficient normal surrounding parenchymal tissue to
provide additional information to allow for proper image registration of the two data sets. The pretreatment data set is registered on a
voxel-by-voxel basis with a posttreatment initiation data set. Application of suitable CIs for detection of significant change between the
interval exams provides for quantification of ADC changes within the tumor. These can be displayed as a joint density plot with regions
color coded to identify the changes when mapped back to the anatomic MR image for spatial visualization.
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basis. One of the challenges is the difficulty in obtaining test-retest
data for imaging metric validation due to a more complicated study
design and overall reduction in study compliance between clinical sites.
Additional methods for analyzing registration algorithms using real
data are possible wherein correspondence points have been identified
manually. The challenge with this scenario is that user-identified
points also have a noise spectrum, sometimes large. However, such
analysis can still yield valuable, quantifiable insight into the power
of registration solutions [47]. Shared human image data sets are also
becoming more readily available with projects like the QIN. The
emerging paradigm of shared research image databases provides a
valuable paradigm for making test data accessible and sharing new
computational approaches to problems. Overall, routine clinical use
of the PRM biomarker response metric will likely require solid corre-
lation with clinical outcome metrics such as histopathology for residual
disease assessment.
Change detection using PRM is quantitative and the level of varia-
tion that indicates change must be verified for each scenario, particu-
larly when measuring interval change in the absence of personalized
test-retest data. Establishment of statistical cutoff values that indicate
a detectable change in quantitative value can be achieved using two
different approaches that evaluate either contralateral tissue pretreat-
ment and posttreatment initiation or tumor in a test-retest approach
that consists of acquiring duplicate scans over a very short time inter-
val. Both approaches allow for the variation of quantitative values in
the absence of changes in tissue/tumor anatomy and physiology to
be evaluated, which arise from the combined noise of the imaging
system and registration algorithm. Although the test-retest provides
direct assessment of noise from the tumor, it is more challenging
for imaging modalities that require contrast injection and/or radiation
[e.g., CT, PET, single-photon emission computerized tomography
(SPECT), and DCE-MRI]. The use of normal contralateral tissue as
a normalization standard on an individual patient can be applied to
assess the variability of the imaging metric under investigation [8].
However, care would be needed to ensure that any contralateral or
comparison tissue was not changed physically, anatomically, or thera-
peutically, which may result in an overestimation of the threshold,
thus reducing PRM’s accuracy in detecting therapeutic change in
tumors. From an end-point perspective, scanner variation could yield
different distributions of values for the same region (a serious challenge
in CT and also MR) that needs to be accounted for in any change
detection thresholds. To go one step further and incorporate multi-
modality fusion for breast imaging and facilitate the use of, for example,
PET imaging will require continued attention to each of the elements
of biomarker development to ensure similar robustness [48].
The PRM cutoff has an effect on the sensitivity of the technique
and has been evaluated either by testing the predictive potential of
PRM using various cutoffs or deriving a more complex Bayesian model
for defining the cutoff [8,9]. Although the predictive potential of PRM
was improved for these cases, the improvement gained was minor com-
pared to the simple derived cutoff from the 95% CI. As the cutoff is
integral for PRM methodology, it will have to be determined for each
unique case that may include tumor type, tumor location, and imaging
modality. From our experience, calculation of the 95% CI provides
a simplified approach to determine cutoffs for changes in quantitative
values beyond system and registration noise.
Finally, to test any alternative response marker requires the avail-
ability of a near production quality method for processing data sets.
The University of Michigan QIN research team has partnered with
Imbio, LLC, a company that is focused on development and migra-
tion of PRM to a web-based platform to provide ease of access to
automatic processing and report generation. The Imbio cloud–based
approach will implement robust software tools with minimal user
interaction and automated quality control to ensure fidelity of analysis.
Development of this tool would make PRM accessible across multiple
sites, thus providing a robust image registration algorithm for PRM
analysis as a shareable tool to the overall research community.
Conclusion
Voxel-based image analysis required for following heterogeneous
tumor response to therapy can be accomplished through access to
high-quality MR data and use of appropriate image registration
algorithms with careful selection of thresholds for determination of
significant treatment-induced change along with appropriate quality
controls. This paper presented approaches that can be used to devel-
op and validate PRM-based methods as early response metrics for
prediction and stratification of breast cancer responders from non-
responders using DW-MRI scans. The overarching goal of provid-
ing quantitative imaging biomarkers that will allow oncologists to
remove patients from ineffective therapies quickly will, in the long
term, likely improve significantly the overall clinical management
of patients with breast cancer through individualized care.
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